Healthcare / BiotechnologyNYSE American
$0.35
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-16.9M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
1/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$16M
P/E
N/A
•EV/EBITDA
N/A
•ROE
N/A
•Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-23.7M · FCF $-16.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $0.00 | $2.6M |
| Net Income | $-23.7M | $-23.7M | $-25.7M | $-18.3M | $-19.7M | $-14.3M | $-10.0M | $-15.3M | $-13.4M | $-15.2M | $-27.3M | $-43.7M | $-19.8M | $-12.3M | $-17.1M | $-8.1M | $-1.7M |
| EBITDA | $-23.9M | $-23.9M | $-26.2M | $-21.3M | $-21.5M | $-14.2M | $-10.0M | $-15.4M | $-17.3M | $-26.0M | $-39.1M | $-40.9M | $-20.5M | $-12.3M | — | — | — |
| EPS | -2.08 | -2.08 | -19.03 | -28.48 | -1.31 | -1.90 | -0.66 | — | — | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -65.5% |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-16.7M | $-16.7M | $-16.9M | $-19.2M | $-19.2M | $-12.9M | $-12.2M | $-13.9M | $-17.3M | $-20.4M | $-28.5M | $-39.4M | $-16.1M | $-7.8M | $-8.9M | $-2.9M | $-1.2M |
| Returns | |||||||||||||||||
| ROE | — | — | — | — | — | -21.8% | 210.7% | -840.4% | -78.3% | 1014.3% | -708.8% | -272.5% | -207.0% | -80.9% | -131.0% | -115.4% | -47.8% |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -100.0% | — |
| EPS Growth | 89.1% | 89.1% | 33.2% | -2074.0% | 31.1% | -187.9% | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.